Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway
Immunity, Inflammation and Disease · 2025-04 · 13 (4)
DOI: 10.1002/iid3.70155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 07.04.2025. Verfasst von Ziyang Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Trauma-Emergency & Critical Care Medicine Center, Shanghai Fifth People's Hospital Affiliated to Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Receptors, Cytoplasmic and Nuclear, Sepsis, Bile Acids and Salts. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Research project of Shanghai Fifth People's Hospital Affiliated to Fudan University (Incubation Project) (2022WYFY01) and Shanghai Min….
Themen: Sepsis
Abstract (Originalsprache)
Objective
The study aims to investigate the mechanism of Farnesoid X receptor (FXR) activation in sepsis‐induced abnormal bile acid metabolism and the metabolism status of each bile acid type.
Methods
The sepsis mouse model was developed via lipopolysaccharide intraperitoneal injection and confirmed via hematoxylin and eosin (H&E) staining. FXR agonist activated the FXR/fibroblast growth factor (FGF)15/FGFR pathway via quantitative real‐time polymerase chain reaction and Western blot. Consequently, metabolomics and bioinformatics analysis were conducted to identify the alterations in each kind of bile acid content following FXR agonist/inhibitor intervention.
Results
The H&E staining indicated that FXR activation alleviates the liver injury of the sepsis mouse model. The increased FGF15 and FXFR expression levels and decreased CYP7A1 demonstrated FXR/FGF15/FGFR pathway activation following FXR agonist treatment. Furthermore, total bile acid, interleukin (IL)‐6, and tumor necrosis factor‐α concentrations were downregulated after FXR activation, whereas IL‐10 concentration was upregulated, indicating the alleviated effect of FXR agonist in sepsis. Consequently, metabolomics and bioinformatics analysis determined that T‐a‐MCA were downregulated in both FXR agonist and inhibitor groups, whereas six bile acid types were altered in the control group.
Conclusion
FXR activation was crucial in alleviating sepsis‐induced hepatic injury and cholestasis through the FGF15/FGFR signaling pathway, and FXR may act as a potential preventive and intervention target of sepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trauma-Emergency & Critical Care Medicine Center, Shanghai Fifth People's Hospital Affiliated to Fudan University, Shanghai, China.
- Joint Center for Translational Medicine, Shanghai Fifth People's Hospital, Fudan University and School of Life Science, East China Normal University, Shanghai, China.
ORCID-Profile: Hui Chen, Jianguo Tang
Förderung
- This study was funded by Research project of Shanghai Fifth People's Hospital Affiliated to Fudan University (Incubation Project) (2022WYFY01) and Shanghai Min…
Zitieren
APA
Zhou, Z., Xu, D., Huang, L., Cui, Y., Chen, H., & Tang, J. (2025). Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway. Immunity, Inflammation and Disease, 13(4). https://doi.org/10.1002/iid3.70155
Vancouver
Zhou Z, Xu D, Huang L, Cui Y, Chen H, Tang J. Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway. Immunity, Inflammation and Disease. 2025;13(4). doi:10.1002/iid3.70155
BibTeX
@article{Zhou2025,
author = {Zhou, Ziyang and Xu, Dan and Huang, Liou and Cui, Yuhui and Chen, Hui and Tang, Jianguo},
title = {Farnesoid X Receptor Regulated Sepsis‐Induced Abnormal Bile Acid Metabolism via the Fibroblast Growth Factor 15/Fibroblast Growth Factor Receptor 4 Pathway},
journal = {Immunity, Inflammation and Disease},
year = {2025},
volume = {13},
number = {4},
doi = {10.1002/iid3.70155}
}
EUVIMED